Markets:

Overview

News

Currencies

International

Treasuries

Enlivex Ltd. - Ordinary Shares (NQ:ENLV)

0.8824 +0.0224 (+2.60%)

Streaming Delayed Price Updated: 10:52 AM EDT, Jun 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enlivex Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

February 15, 2023

From Enlivex Therapeutics Ltd

Via GlobeNewswire

Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

January 25, 2023

From Enlivex Therapeutics Ltd

Via GlobeNewswire

Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium

January 04, 2023

From Enlivex Therapeutics Ltd

Via GlobeNewswire

A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial

December 07, 2022

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients.

Via TheNewswire.com

A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial

December 07, 2022

By Rachael Green, Benzinga

Via News Direct

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

December 06, 2022

Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.

Via TheNewswire.com

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

December 06, 2022

By Ernest Dela Aglanu, Benzinga

Via News Direct

Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update

December 05, 2022

From Enlivex Therapeutics Ltd

Via GlobeNewswire

First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM

December 02, 2022

By Rachael Green, Benzinga

Via News Direct

First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM

December 02, 2022

On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra. The novel off-the-shelf cell therapy is designed to help break...

Via TheNewswire.com

Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors

December 01, 2022

The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunotherapy drug-candidate AllocetraTM.

Via TheNewswire.com

Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors

December 01, 2022

By Rachael Green, Benzinga

Via News Direct

FDA Clears Enlivex Therapeutics' IND Application To Study Allocetra™ in Patients with Advanced Solid Malignancies ↗

November 29, 2022

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that the U.S. Food & Drug Administration (FDA) had cleared an Investigational New Drug (IND) application to study Allocetra™ in patients with...

Via Benzinga

Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies

November 28, 2022

From Enlivex Therapeutics Ltd

Via GlobeNewswire

First Patients Dosed in Phase I/II Trial of Enlivex's Off-the-Shelf Cell Therapy Candidate, AllocetraTM ↗

November 22, 2022

On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dose

Via Benzinga

Enlivex Doses First Patient in Phase I/II Trial to Evaluate Allocetra™ for Advanced Solid Tumor Treatment ↗

November 15, 2022

Enlivex Therapeutics Ltd.

Via Benzinga

Enlivex: Meet The Company Championing A Paradigm Shift In Cancer Treatment ↗

November 15, 2022

Via Benzinga

Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

November 15, 2022

From Enlivex Therapeutics Ltd

Via GlobeNewswire

Enlivex to Present at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer

November 10, 2022

From Enlivex Therapeutics Ltd

Via GlobeNewswire

A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial ↗

November 01, 2022

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients.

Via Benzinga

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers ↗

October 25, 2022

Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.

Via Benzinga

Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors ↗

October 06, 2022

The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunothera

Via Benzinga

Enlivex to Present at the 4th Macrophage-Directed Therapies Summit

October 03, 2022

From Enlivex Therapeutics Ltd

Via GlobeNewswire

Roger Pomerantz And Shai Novik Say They're Racing To Change The Odds Of Cancer Treatments ↗

July 14, 2022

Cancer research has come a long way in the past few decades, pioneering treatments like chemotherapy and radiation treatments that have become essential weapons in the fight against this deadly and...

Via Benzinga

Changing The Landscape Of Cancer Therapy With Macrophages? How One Israeli Company Reports It's Looking To Do Just That ↗

July 05, 2022

One of the chief challenges cancer researchers face today is finding a way to outsmart the disease’s defense mechanisms.

Via Benzinga

Reprogramming Imbalanced Macrophage Populations May Play A Key Role In Resolving Cancer And Various Inflammatory Disorders ↗

June 23, 2022

Shai Novik, Executive Chairman of the Board at Enlivex Therapeutics, Ltd. (NASDAQ: ENLV), was a guest speaker at Benzinga’s All Access on June 17th, 2022.

Via Benzinga

Monkeypox Could Reportedly Trigger An Uptick In Sepsis Cases But This Israeli Biotech Company Says It May Have Found A Treatment ↗

June 17, 2022

As the mysterious monkeypox outbreak has many scientists on heightened alert, the rare virus could pose an additional threat to a global population still reeling from the COVID-19 pandemic.

Via Benzinga

Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments? ↗

June 14, 2022

Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in...

Via Benzinga

Should Biotech Be On The Critical List? ↗

May 11, 2022

The risk-off market has played havoc with the biotechs where the fundamentals have not changed as much as the valuation.

Via Talk Markets

51 Biggest Movers From Yesterday ↗

April 07, 2022

Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares climbed 79.7% to close at $3.63 on Wednesday. Advent Technologies and Hyundai Motor Company entered into...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.